<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:02:50Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10727397" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10727397</identifier>
        <datestamp>2023-12-19</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jah38919" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10727397</article-id>
              <article-id pub-id-type="pmcid">PMC10727397</article-id>
              <article-id pub-id-type="pmc-uid">10727397</article-id>
              <article-id pub-id-type="pmid">37889172</article-id>
              <article-id pub-id-type="pmid">37889172</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.123.031611</article-id>
              <article-id pub-id-type="publisher-id">JAH38919</article-id>
              <article-id pub-id-type="other">JAHA/2023/031611-T</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Stroke</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Ticagrelor Versus Clopidogrel in Minor Stroke or <styled-content style="fixed-case" toggle="no">Transient Ischemic Attack</styled-content> With Intracranial Artery Stenosis: A Post Hoc Analysis of <styled-content style="fixed-case" toggle="no">CHANCE</styled-content>‐2</article-title>
                <alt-title alt-title-type="right-running-head">Ticagrelor vs Clopidogrel in Stroke/<styled-content style="fixed-case" toggle="no">TIA</styled-content> With <styled-content style="fixed-case" toggle="no">ICAS</styled-content>
</alt-title>
                <alt-title alt-title-type="left-running-head">Wang et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah38919-cr-0001" contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Chunjuan</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1627-5004</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="jah38919-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="jah38919-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="jah38919-note-0001" ref-type="author-notes">
                    <sup>*</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0002" contrib-type="author">
                  <name>
                    <surname>Jia</surname>
                    <given-names>Weili</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7142-1414</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-note-0001" ref-type="author-notes">
                    <sup>*</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0003" contrib-type="author">
                  <name>
                    <surname>Jing</surname>
                    <given-names>Jing</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9822-5758</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="jah38919-note-0001" ref-type="author-notes">
                    <sup>*</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0004" contrib-type="author">
                  <name>
                    <surname>Meng</surname>
                    <given-names>Xia</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0005" contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Anxin</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4351-2877</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0006" contrib-type="author">
                  <name>
                    <surname>Xu</surname>
                    <given-names>Qin</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8039-709X</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0007" contrib-type="author">
                  <name>
                    <surname>Zhang</surname>
                    <given-names>Xinmiao</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0008" contrib-type="author">
                  <name>
                    <surname>Pan</surname>
                    <given-names>Yuesong</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3082-6789</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0009" contrib-type="author">
                  <name>
                    <surname>Xie</surname>
                    <given-names>Xuewei</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8154-1957</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0010" contrib-type="author">
                  <name>
                    <surname>Johnston</surname>
                    <given-names>S. Claiborne</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2912-0714</contrib-id>
                  <xref rid="jah38919-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0011" contrib-type="author">
                  <name>
                    <surname>Bath</surname>
                    <given-names>Philip M.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2734-5132</contrib-id>
                  <xref rid="jah38919-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0012" contrib-type="author">
                  <name>
                    <surname>Lin</surname>
                    <given-names>Jinxi</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-0995-0541</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0013" contrib-type="author">
                  <name>
                    <surname>Jiang</surname>
                    <given-names>Yong</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7700-6054</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0014" contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Hao</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0015" contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Yilong</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2725-2788</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0016" contrib-type="author">
                  <name>
                    <surname>Zhao</surname>
                    <given-names>Xingquan</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8345-5147</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0017" contrib-type="author">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Liping</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2943-055X</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38919-cr-0018" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Li</surname>
                    <given-names>Zixiao</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4713-5418</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="jah38919-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="jah38919-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="jah38919-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <address>
                    <email>lizixiao2008@hotmail.com</email>
                  </address>
                </contrib>
                <contrib id="jah38919-cr-0019" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Yongjun</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9976-2341</contrib-id>
                  <xref rid="jah38919-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah38919-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="jah38919-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="jah38919-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="jah38919-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="jah38919-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                  <address>
                    <email>yongjunwang@ncrcnd.org.cn</email>
                  </address>
                </contrib>
                <contrib id="jah38919-cr-0020" contrib-type="author">
                  <collab collab-type="authors">for the CHANCE‐2 Investigators</collab>
                  <xref rid="jah38919-note-0002" ref-type="author-notes">
                    <sup>†</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jah38919-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Vascular Neurology, Department of Neurology</named-content>
                <institution>Beijing Tiantan Hospital, Capital Medical University</institution>
                <city>Beijing</city>
                <country country="CN">China</country>
              </aff>
              <aff id="jah38919-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">China National Clinical Research Center for Neurological Diseases</named-content>
                <institution>Beijing Tiantan Hospital, Capital Medical University</institution>
                <city>Beijing</city>
                <country country="CN">China</country>
              </aff>
              <aff id="jah38919-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Advanced Innovation Center for Human Brain Protection</named-content>
                <institution>Capital Medical University</institution>
                <city>Beijing</city>
                <country country="CN">China</country>
              </aff>
              <aff id="jah38919-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences</institution>
                <city>Beijing</city>
                <country country="CN">China</country>
              </aff>
              <aff id="jah38919-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <institution>National Center for Healthcare Quality Management in Neurological Diseases</institution>
                <city>Beijing</city>
                <country country="CN">China</country>
              </aff>
              <aff id="jah38919-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <institution>Chinese Institute for Brain Research</institution>
                <city>Beijing</city>
                <country country="CN">China</country>
              </aff>
              <aff id="jah38919-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <institution>Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences</institution>
                <city>Shanghai</city>
                <country country="CN">China</country>
              </aff>
              <aff id="jah38919-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <named-content content-type="organisation-division">Dell Medical School</named-content>
                <institution>University of Texas at Austin</institution>
                <city>Austin</city>
                <named-content content-type="country-part">TX</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jah38919-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Stroke Trials Unit, Division of Clinical Neuroscience</named-content>
                <institution>University of Nottingham</institution>
                <city>Nottingham</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Zixiao Li, MD, PhD and Yongjun Wang, MD, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 119, South 4th Ring West Road, Fengtai District, Beijing 100070, China. Email: <email>lizixiao2008@hotmail.com</email>; <email>yongjunwang@ncrcnd.org.cn</email>
<break/>
</corresp>
                <fn fn-type="equal" id="jah38919-note-0001">
                  <label>*</label>
                  <p>C. Wang, W. Jia, and J. Jing contributed equally.</p>
                </fn>
                <fn id="jah38919-note-0002">
                  <label>†</label>
                  <p>A complete list of the CHANCE‐2 Investigators can be found in the Supplemental Material.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>27</day>
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>07</day>
                <month>11</month>
                <year>2023</year>
              </pub-date>
              <volume>12</volume>
              <issue seq="440">21</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v12.21</issue-id>
              <elocation-id>e031611</elocation-id>
              <history>
                <date date-type="received">
                  <day>01</day>
                  <month>8</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>26</day>
                  <month>9</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <!--Copyright &#x000a9; 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell-->
                <copyright-statement content-type="article-copyright">© 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-12-e031611.pdf"/>
              <abstract>
                <sec id="jah38919-sec-0001">
                  <title>Background</title>
                  <p>This study aimed to investigate the efficacy and safety of ticagrelor–aspirin versus clopidogrel–aspirin in Chinese patients by the presence and clinical presentation of intracranial artery stenosis (ICAS) using randomized trial data from the CHANCE‐2 (Clopidogrel in High‐Risk Patients With Acute Nondisabling Cerebrovascular Events‐II) trial.</p>
                </sec>
                <sec id="jah38919-sec-0002">
                  <title>Methods and Results</title>
                  <p>A total of 6412 patients with minor stroke or transient ischemic attack who carried <italic toggle="no">CYP2C19</italic> loss‐of‐function alleles were randomized to either the ticagrelor–aspirin or clopidogrel–aspirin group. Patients without imaging of the intracranial artery were excluded from the nonprespecified subgroup analysis of CHANCE‐2. All patients included were classified into the following groups: without ICAS, symptomatic ICAS, or asymptomatic ICAS. The primary efficacy outcome was new strokes within 90 days. There were 5893 patients (median age, 64.8 years; 33.9% women) included, and 172 (4.9%), 171 (10.5%), and 57 (7.7%) cases of new strokes occurred within 90 days in the without ICAS, with symptomatic ICAS, and with asymptomatic ICAS groups, respectively. Ticagrelor–aspirin was associated with reduced risk of new stroke in patients without ICAS (62 [3.5%] versus 110 [6.3%]; hazard ratio [HR], 0.57 [95% CI, 0.41–0.78]) but not in those with symptomatic ICAS (HR, 0.77 [95% CI, 0.56–1.05]) or in those with asymptomatic ICAS (HR, 0.77 [95% CI, 0.43–1.38]) compared with clopidogrel–aspirin (<italic toggle="no">P</italic> for interaction=0.14). There were no significant differences in the proportion of severe or moderate bleeding events among different ICAS groups.</p>
                </sec>
                <sec id="jah38919-sec-0003">
                  <title>Conclusions</title>
                  <p>Patients without ICAS received a significantly greater benefit from ticagrelor–aspirin than clopidogrel–aspirin after minor ischemic stroke or transient ischemic attack, and there was no statistically significant difference between treatments in patients with symptomatic ICAS or asymptomatic ICAS.</p>
                </sec>
                <sec id="jah38919-sec-0004">
                  <title>Registration</title>
                  <p>URL: <ext-link xlink:href="https://www.clinicaltrials.gov" ext-link-type="uri">https://www.clinicaltrials.gov</ext-link>; Unique identifier: NCT04078737.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jah38919-kwd-0001">clopidogrel</kwd>
                <kwd id="jah38919-kwd-0002"><italic toggle="no">CYP2C19</italic> loss‐of‐function alleles</kwd>
                <kwd id="jah38919-kwd-0003">intracranial artery stenosis</kwd>
                <kwd id="jah38919-kwd-0004">ticagrelor</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Ischemic Stroke</kwd>
                <kwd>Clinical Studies</kwd>
                <kwd>Platelets</kwd>
                <kwd>Genetics</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Natural Science Foundation of China
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>92046016</award-id>
                  <award-id>82171 270</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>Beijing Natural Science Foundation
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100004826</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>Z200016</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>Beijing Municipal Committee of Science and Technology</funding-source>
                  <award-id>Z201100005620010</award-id>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences</funding-source>
                  <award-id>2019‐2M‐5‐029</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="3"/>
                <page-count count="12"/>
                <word-count count="6661"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>07 November 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.5 mode:remove_FC converted:20.11.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <fn-group id="jah38919-ntgp-0001">
                <fn id="jah38919-note-0003">
                  <p>This article was sent to Meng Lee, MD, Guest Editor, for review by expert referees, editorial decision, and final disposition.</p>
                </fn>
                <fn id="jah38919-note-0004">
                  <p>Supplemental Material is available at <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.123.031611" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.123.031611</ext-link>
</p>
                </fn>
                <fn id="jah38919-note-0005">
                  <p>For Sources of Funding and Disclosures, see page 11.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah38919-body-0001">
            <def-list list-content="abbreviations" id="jah38919-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term id="jah38919-li-0001">asICAS</term>
                <def id="jah38919-li-0002">
                  <p>asymptomatic intracranial artery stenosis</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38919-li-0003">ICAS</term>
                <def id="jah38919-li-0004">
                  <p>intracranial artery stenosis</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38919-li-0005">sICAS</term>
                <def id="jah38919-li-0006">
                  <p>symptomatic intracranial artery stenosis</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah38919-blkfxd-0001">
                <caption>
                  <title>Clinical Perspective</title>
                </caption>
                <sec id="jah38919-sec-0007">
                  <title>What Is New?</title>
                  <p>
                    <list list-type="bullet" id="jah38919-list-0001">
                      <list-item id="jah38919-li-0007">
                        <p>The guided selection of antiplatelet therapy according to the results of genetic testing has allowed for the optimization of the choice of agent in patients undergoing percutaneous coronary intervention, which has improved prognostic outcomes.</p>
                      </list-item>
                      <list-item id="jah38919-li-0008">
                        <p>Whether the guided selection of antiplatelet therapy based on genetic testing is effective for preventing recurrent stroke in patients with or without intracranial artery stenosis remains unclear.</p>
                      </list-item>
                      <list-item id="jah38919-li-0009">
                        <p>This study is the first to investigate the efficacy and safety of ticagrelor–aspirin versus clopidogrel–aspirin in Chinese patients who were carriers of <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles by the presence and clinical presentation of intracranial artery stenosis.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
                <sec id="jah38919-sec-0008">
                  <title>What Are the Clinical Implications?</title>
                  <p>
                    <list list-type="bullet" id="jah38919-list-0002">
                      <list-item id="jah38919-li-0010">
                        <p>Our findings suggest that patients without intracranial artery stenosis received a significantly greater benefit from ticagrelor–aspirin than clopidogrel–aspirin after minor ischemic stroke or transient ischemic attack, and there was no statistically significant difference between treatments in patients with symptomatic intracranial artery stenosis or asymptomatic intracranial artery stenosis.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
            </p>
            <p>Intracranial artery stenosis (ICAS), one of the most common causes of ischemic stroke, carries a high risk of recurrence, especially among patients with acute minor ischemic stroke and transient ischemic attack (TIA).<xref rid="jah38919-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="jah38919-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="jah38919-bib-0003" ref-type="bibr"><sup>3</sup></xref> It has been demonstrated that aggressive medical therapy with clopidogrel plus aspirin is associated with a lower risk of recurrent stroke in patients with ICAS when compared with aggressive medical therapy plus stenting.<xref rid="jah38919-bib-0004" ref-type="bibr"><sup>4</sup></xref> However, the subgroup analysis performed in the CHANCE (Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack) trial did not show that clopidogrel plus aspirin was superior to aspirin alone in preventing stroke recurrence at 90 days for patients with ICAS (11.3% versus 13.6%).<xref rid="jah38919-bib-0005" ref-type="bibr"><sup>5</sup></xref> Clopidogrel is less effective at preventing stroke recurrence in carriers of <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles, which are present in 25% of the Asian population,<xref rid="jah38919-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="jah38919-bib-0007" ref-type="bibr"><sup>7</sup></xref> and pharmacogenomics might account for the lack of superiority of clopidogrel to aspirin alone in this subgroup analysis.<xref rid="jah38919-bib-0008" ref-type="bibr"><sup>8</sup></xref> Although it had been demonstrated that ticagrelor or ticagrelor–aspirin was superior to aspirin alone in patients with atherosclerotic stenosis in the subgroup analyses performed in the SOCRATES (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)<xref rid="jah38919-bib-0009" ref-type="bibr"><sup>9</sup></xref> and THALES (The Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death) trials,<xref rid="jah38919-bib-0010" ref-type="bibr"><sup>10</sup></xref> no previous antiplatelet studies have compared ticagrelor with clopidogrel, both of which are P2Y12 receptor blockers, in Asian patients who are carriers of the <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles and have ICAS and ischemic stroke or TIA.</p>
            <p>Recently, the guided selection of antiplatelet therapy according to the results of genetic testing has allowed for the optimization of the choice of agent in patients undergoing percutaneous coronary intervention, which has improved prognostic outcomes.<xref rid="jah38919-bib-0011" ref-type="bibr"><sup>11</sup></xref> In addition, in the CHANCE‐2 (Ticagrelor or Clopidogrel With Aspirin in High‐Risk Patients With Acute Nondisabling Cerebrovascular Events‐II) trial, ticagrelor or clopidogrel with aspirin was administered to high‐risk patients, and the results revealed that ticagrelor plus aspirin significantly reduced the risk of stroke at 90 days compared with clopidogrel plus aspirin in patients who were carriers of <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles (hazard ratio [HR], 0.77 [95% CI, 0.64–0.94]), and patients without symptomatic ICAS (sICAS) received a significantly greater benefit from ticagrelor–aspirin than clopidogrel–aspirin (HR, 0.62 [95% CI, 0.47–0.81]).<xref rid="jah38919-bib-0012" ref-type="bibr"><sup>12</sup></xref> However, whether the guided selection of antiplatelet therapy based on genetic testing is effective for preventing recurrent stroke in patients with or without ICAS remains unclear. Therefore, we aimed to investigate the efficacy and safety of ticagrelor–aspirin versus clopidogrel–aspirin in patients with acute minor ischemic stroke or TIA by the presence and clinical presentation of ICAS who carry <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles as identified by genetic testing.</p>
            <sec sec-type="methods" id="jah38919-sec-0009">
              <title>METHODS</title>
              <p>Requests for access to the data reported in this article will be considered by the corresponding author.</p>
              <sec id="jah38919-sec-0010">
                <title>Study Design and Participants</title>
                <p>This study was a post hoc and nonprespecified subgroup analysis of the CHANCE‐2 trial, which was conducted as a randomized, double‐blind, controlled trial at 202 centers across mainland China from September 23, 2019 to March 22, 2021. All site investigators who were trained determined the enrollment. The protocol of the CHANCE‐2 trial was described in detail previously.<xref rid="jah38919-bib-0013" ref-type="bibr"><sup>13</sup></xref> The inclusion criteria of this current study were as follows: (1) ≥40 years of age; (2) had a minor acute ischemic stroke (National Institutes of Health Stroke Scale score of ≤3) or high‐risk TIA, which was defined by an ABCD<xref rid="jah38919-bib-0002" ref-type="bibr"><sup>2</sup></xref> score of ≥4 (the ABCD<sup>2</sup> score is based on age, blood pressure, clinical features, duration of TIA, and the presence or absence of diabetes; range, 0–7, with higher scores indicating a higher risk of stroke); (3) a carrier of <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles; (4) had received the study drugs within 24 hours of symptom onset; and (5) signed informed consent. Patients without imaging of the intracranial artery or with only transcranial Doppler for the intracranial artery were excluded from the analysis. This study followed Consolidated Standards of Reporting Trials reporting guidelines for randomized controlled trials.<xref rid="jah38919-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="jah38919-bib-0015" ref-type="bibr"><sup>15</sup></xref> The trial was approved by the ethics committees at Beijing Tiantan Hospital, Capital Medical University, and at each participating site and was performed according to the Good Clinical Practice guidelines.</p>
              </sec>
              <sec id="jah38919-sec-0011">
                <title>Randomization and Treatment</title>
                <p>After rapid point‐of‐care genotyping, eligible patients carrying <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles were randomly assigned in a 1:1 ratio to receive ticagrelor–aspirin or clopidogrel–aspirin within 24 hours after symptom onset. Each patient was randomly assigned a number corresponding to a medication kit that he or she was given through a centralized randomization computer program. Patients in the ticagrelor–aspirin group received the clopidogrel placebo and a 180‐mg loading dose of ticagrelor on day 1, followed by 90 mg twice daily for days 2 to 90. Patients in the clopidogrel–aspirin group received the ticagrelor placebo and a 300‐mg loading dose of clopidogrel on day 1, followed by 75 mg daily for days 2 to 90. Both groups received a 75‐ to 300‐mg loading dose of aspirin on day 1, followed by 75 mg daily for 21 days. Additional information on randomization and treatment is provided in the protocol.<xref rid="jah38919-bib-0013" ref-type="bibr"><sup>13</sup></xref>
</p>
              </sec>
              <sec id="jah38919-sec-0012">
                <title>Assessment and Definition of <styled-content style="fixed-case" toggle="no">ICAS</styled-content>
</title>
                <p>During the CHANCE‐2 trial, the enrolled patients at all participating sites received a routine full assessment of brain tissue and the intra−/extracranial arteries by magnetic resonance imaging (including at least T1, fluid attenuated inversion recovery, diffusion‐weighted imaging, and magnetic resonance [MR] angiography) as the first choice, or computed tomography (CT) scan (including CT angiography) if magnetic resonance imaging was contraindicated or unavailable, and carotid ultrasound or digital subtraction angiography if CT angiography was also contraindicated or unavailable. We assessed the intracranial arteries, including the distal internal carotid, middle cerebral (M1 and M2), anterior cerebral, posterior cerebral, basilar arteries, and an intracranial portion of the vertebral (V4), and the extracranial arteries, including subclavian, common carotid, proximal internal carotid, and the extracranial portion of the vertebral (V1, V2, V3). Imaging of the ipsilateral or contralateral arteries and sICAS or asymptomatic intracranial artery stenosis (asICAS) was independently evaluated by 2 neurologists (C.W. and X. Zhang), who were blinded to the clinical information and consulting neuroradiologist's report. If there was a disagreement, a third assessment (J.J.) was adjudicated. All assessors were blinded to the patient's baseline and outcome information.</p>
                <p>ICAS was defined as at least 50% ipsilateral or contralateral stenosis of the intracranial large arteries based on MR and/or CT angiography. The degree of stenosis was assessed using the WASID (Warfarin–Aspirin Symptomatic Intracranial Disease) method.<xref rid="jah38919-bib-0016" ref-type="bibr"><sup>16</sup></xref> Based on the recent clinical manifestations and brain parenchymal imaging results, eligible ICAS is classified as sICAS (an ICAS with the most recent ischemic stroke or TIA involved in the region of arterial stenosis) or asICAS (an ICAS with the most recent ischemic stroke or TIA but not involved in the region of arterial stenosis).<xref rid="jah38919-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="jah38919-bib-0017" ref-type="bibr"><sup>17</sup></xref> Patients without ICAS belonged to the without ICAS group.</p>
              </sec>
              <sec id="jah38919-sec-0013">
                <title>Outcome Measure</title>
                <p>The efficacy primary outcome was a new ischemic or hemorrhagic stroke within 90 days. Secondary efficacy outcomes included new ischemic stroke within 90 days, new ischemic or hemorrhagic stroke within 30 days, a vascular event (composite of stroke, TIA, myocardial infarction, and vascular death), disabling stroke (with modified Rankin Scale [mRS] score ≥2) within 90 days, and ordinal severity of stroke or TIA within 90 days (the severity was measured by a 6‐level scale, including subsequent stroke or TIA events and the mRS score at 3 months as follows: fatal stroke [stroke with subsequent score on the mRS of 6], severe stroke [stroke with the subsequent score on the mRS of 4 or 5], moderate stroke [stroke with subsequent score on the mRS of 2 or 3], or mild stroke [stroke with subsequent score on the mRS of 0 or 1], TIA, and no stroke or TIA). The primary safety outcome was severe or moderate bleeding defined according to the GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) criteria at 90 days.<xref rid="jah38919-bib-0018" ref-type="bibr"><sup>18</sup></xref> Secondary safety outcomes included any bleeding, mild bleeding, and death through 90 days of follow‐up. Members of an independent clinical‐event adjudication committee who were unaware of the trial group assignments confirmed all reported efficacy and safety outcomes based on available medical records, including imaging.</p>
              </sec>
              <sec id="jah38919-sec-0014">
                <title>Statistical Analysis</title>
                <p>We presented continuous variables as the median (interquartile range [IQR]) and categorical variables as number (percent). The baseline characteristics of the ticagrelor–aspirin group and clopidogrel–aspirin group (and the different ICAS subgroups) were assessed by the Kruskal‐Wallis test for continuous variables and the χ<sup>2</sup> test for categorical variables. The cumulative incidence of the efficacy outcome of any stroke or ischemic stroke event was identified with a Kaplan‐Meier analysis during the 90‐day follow‐up for each group, and the significance of differences between groups was tested by the log‐rank test. Differences in the 90‐day end points between groups were estimated by the Cox proportional hazards model, with trail centers set as a random effect. HRs with 95% CIs were reported. Shift analysis was performed to compare the secondary outcome of the ordinal severity of stroke or TIA between the ticagrelor–aspirin group and clopidogrel–aspirin group. The common odds ratio and 95% CIs were calculated through ordinal logistic regression. To evaluate whether the effect of treatment on outcomes would be modified by any ICAS, the interaction effect of treatment and ICAS was tested in the Cox models or logistic regression models. When there were multiple events of the same type, the time to the first event was used in the model. Data from patients who experienced a clinical event at the end of the study or at the time of withdrawal from the study were censored at their last follow‐up assessment.</p>
                <p>Sensitivity analysis was used to verify the stability of the model after adjusting the variables with statistical differences in Table <xref rid="jah38919-tbl-0001" ref-type="table">1</xref> including age, sex, systolic blood pressure, body mass index, previous history of hypertension, diabetes, ischemic stroke, myocardial infarction and coronary artery disease, current smoking, and previous medication of antiplatelet and lipid‐lowering therapy. Furthermore, propensity score matching was performed to balance potential bias. The propensity score was estimated as multivariate logistic regression according to the following variables: age, sex, blood pressure, body mass index, medical history, current smoking, type of <italic toggle="yes">CYP2C19</italic> loss‐of‐function allele carrier, time to randomization after symptom onset, qualifying events, and previous medication. The estimated propensity score matched patients treated with ticagrelor–aspirin in a ratio of 1:1 to patients treated with clopidogrel–aspirin at each ICAS subgroup. We further calculated the efficacy and safety outcomes of ticagrelor–aspirin and clopidogrel–aspirin treatment in patients with anterior or posterior circulation.</p>
                <table-wrap position="float" id="jah38919-tbl-0001" content-type="Table">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline Characteristics of Patients in Different ICAS Groups and With Different Treatments</p>
                  </caption>
                  <table frame="hsides" rules="all">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" style="border-bottom:solid 1px #000000" colspan="1">Characteristic</th>
                        <th align="left" rowspan="3" style="border-bottom:solid 1px #000000" colspan="1">All (n=5893)</th>
                        <th align="left" colspan="6" style="border-bottom:solid 1px #000000" rowspan="1">Group</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Without ICAS, n=3514 (59.6%)</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">With sICAS, n=1634 (27.7%)</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">With asICAS, n=745 (12.7%)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Ticagrelor–aspirin (n=1754)</th>
                        <th align="left" rowspan="1" colspan="1">Clopidogrel–aspirin (n=1760)</th>
                        <th align="left" rowspan="1" colspan="1">Ticagrelor–aspirin (n=837)</th>
                        <th align="left" rowspan="1" colspan="1">Clopidogrel–aspirin (n=797)</th>
                        <th align="left" rowspan="1" colspan="1">Ticagrelor–aspirin (n=365)</th>
                        <th align="left" rowspan="1" colspan="1">Clopidogrel–aspirin (n=380)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, y, median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">64.8 (57.0–71.4)</td>
                        <td align="left" rowspan="1" colspan="1">63.6 (55.9–70.3)</td>
                        <td align="left" rowspan="1" colspan="1">63.9 (56.3–70.4)</td>
                        <td align="left" rowspan="1" colspan="1">65.9 (59.1–73.6)</td>
                        <td align="left" rowspan="1" colspan="1">66.2 (58.0–73.0)</td>
                        <td align="left" rowspan="1" colspan="1">67.5 (59.7–73.5)</td>
                        <td align="left" rowspan="1" colspan="1">65.2 (57.5–72.3)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="8" rowspan="1">Sex, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Women</td>
                        <td align="left" rowspan="1" colspan="1">1996 (33.9)</td>
                        <td align="left" rowspan="1" colspan="1">569 (32.4)</td>
                        <td align="left" rowspan="1" colspan="1">568 (32.3)</td>
                        <td align="left" rowspan="1" colspan="1">306 (36.6)</td>
                        <td align="left" rowspan="1" colspan="1">265 (33.3)</td>
                        <td align="left" rowspan="1" colspan="1">135 (37.0)</td>
                        <td align="left" rowspan="1" colspan="1">153 (40.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Men</td>
                        <td align="left" rowspan="1" colspan="1">3907 (66.1)</td>
                        <td align="left" rowspan="1" colspan="1">1185 (67.5)</td>
                        <td align="left" rowspan="1" colspan="1">1192 (67.7)</td>
                        <td align="left" rowspan="1" colspan="1">531 (63.4)</td>
                        <td align="left" rowspan="1" colspan="1">532 (66.7)</td>
                        <td align="left" rowspan="1" colspan="1">230 (63.0)</td>
                        <td align="left" rowspan="1" colspan="1">227 (59.7)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="8" rowspan="1">Ethnicity<xref rid="jah38919-note-0007" ref-type="table-fn">*</xref>, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Han</td>
                        <td align="left" rowspan="1" colspan="1">5780 (98.1)</td>
                        <td align="left" rowspan="1" colspan="1">1721 (98.1)</td>
                        <td align="left" rowspan="1" colspan="1">1722 (97.8)</td>
                        <td align="left" rowspan="1" colspan="1">818 (97.7)</td>
                        <td align="left" rowspan="1" colspan="1">787 (98.8)</td>
                        <td align="left" rowspan="1" colspan="1">362 (99.2)</td>
                        <td align="left" rowspan="1" colspan="1">370 (97.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other<xref rid="jah38919-note-0008" ref-type="table-fn">†</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">113 (1.9)</td>
                        <td align="left" rowspan="1" colspan="1">33 (1.9)</td>
                        <td align="left" rowspan="1" colspan="1">38 (2.2)</td>
                        <td align="left" rowspan="1" colspan="1">19 (2.3)</td>
                        <td align="left" rowspan="1" colspan="1">10 (1.2)</td>
                        <td align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td align="left" rowspan="1" colspan="1">10 (2.6)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="8" rowspan="1">Blood pressure, mm Hg, median (IQR)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic blood pressure</td>
                        <td align="left" rowspan="1" colspan="1">148 (136–162)</td>
                        <td align="left" rowspan="1" colspan="1">147 (135–160)</td>
                        <td align="left" rowspan="1" colspan="1">147 (135–160)</td>
                        <td align="left" rowspan="1" colspan="1">150 (140–164)</td>
                        <td align="left" rowspan="1" colspan="1">150 (137–163)</td>
                        <td align="left" rowspan="1" colspan="1">149 (136–165)</td>
                        <td align="left" rowspan="1" colspan="1">149 (136–163)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic blood pressure</td>
                        <td align="left" rowspan="1" colspan="1">86 (80–95)</td>
                        <td align="left" rowspan="1" colspan="1">87 (80–95)</td>
                        <td align="left" rowspan="1" colspan="1">86 (80–95)</td>
                        <td align="left" rowspan="1" colspan="1">86 (80–95)</td>
                        <td align="left" rowspan="1" colspan="1">86 (80–94)</td>
                        <td align="left" rowspan="1" colspan="1">86 (79–94)</td>
                        <td align="left" rowspan="1" colspan="1">86 (80–96)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>, median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">24.5 (22.6–26.6)</td>
                        <td align="left" rowspan="1" colspan="1">24.4 (22.7–26.6)</td>
                        <td align="left" rowspan="1" colspan="1">24.2 (22.5–26.3)</td>
                        <td align="left" rowspan="1" colspan="1">24.8 (22.8–26.8)</td>
                        <td align="left" rowspan="1" colspan="1">24.7 (22.8–26.9)</td>
                        <td align="left" rowspan="1" colspan="1">24.8 (22.6–26.7)</td>
                        <td align="left" rowspan="1" colspan="1">24.2 (22.5–26.6)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="8" rowspan="1">Medical history, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td>
                        <td align="left" rowspan="1" colspan="1">4365 (74.1)</td>
                        <td align="left" rowspan="1" colspan="1">1220 (69.6)</td>
                        <td align="left" rowspan="1" colspan="1">1255 (71.3)</td>
                        <td align="left" rowspan="1" colspan="1">679 (81.1)</td>
                        <td align="left" rowspan="1" colspan="1">628 (78.8)</td>
                        <td align="left" rowspan="1" colspan="1">289 (79.1)</td>
                        <td align="left" rowspan="1" colspan="1">294 (77.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes</td>
                        <td align="left" rowspan="1" colspan="1">1887 (32.0)</td>
                        <td align="left" rowspan="1" colspan="1">507 (28.9)</td>
                        <td align="left" rowspan="1" colspan="1">501 (28.5)</td>
                        <td align="left" rowspan="1" colspan="1">319 (38.1)</td>
                        <td align="left" rowspan="1" colspan="1">283 (35.5)</td>
                        <td align="left" rowspan="1" colspan="1">136 (37.3)</td>
                        <td align="left" rowspan="1" colspan="1">141 (37.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dyslipidemia</td>
                        <td align="left" rowspan="1" colspan="1">1644 (27.9)</td>
                        <td align="left" rowspan="1" colspan="1">486 (27.7)</td>
                        <td align="left" rowspan="1" colspan="1">496 (28.2)</td>
                        <td align="left" rowspan="1" colspan="1">248 (29.6)</td>
                        <td align="left" rowspan="1" colspan="1">225 (28.2)</td>
                        <td align="left" rowspan="1" colspan="1">86 (23.6)</td>
                        <td align="left" rowspan="1" colspan="1">103 (27.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous ischemic stroke</td>
                        <td align="left" rowspan="1" colspan="1">1238 (21.0)</td>
                        <td align="left" rowspan="1" colspan="1">289 (16.5)</td>
                        <td align="left" rowspan="1" colspan="1">315 (17.9)</td>
                        <td align="left" rowspan="1" colspan="1">257 (30.7)</td>
                        <td align="left" rowspan="1" colspan="1">220 (27.6)</td>
                        <td align="left" rowspan="1" colspan="1">72 (19.7)</td>
                        <td align="left" rowspan="1" colspan="1">85 (22.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous TIA</td>
                        <td align="left" rowspan="1" colspan="1">83 (1.4)</td>
                        <td align="left" rowspan="1" colspan="1">20 (1.1)</td>
                        <td align="left" rowspan="1" colspan="1">24 (1.4)</td>
                        <td align="left" rowspan="1" colspan="1">19 (2.3)</td>
                        <td align="left" rowspan="1" colspan="1">10 (1.3)</td>
                        <td align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td align="left" rowspan="1" colspan="1">7 (1.8)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Myocardial infarction</td>
                        <td align="left" rowspan="1" colspan="1">83 (1.4)</td>
                        <td align="left" rowspan="1" colspan="1">17 (0.97)</td>
                        <td align="left" rowspan="1" colspan="1">17 (0.97)</td>
                        <td align="left" rowspan="1" colspan="1">22 (2.6)</td>
                        <td align="left" rowspan="1" colspan="1">13 (1.6)</td>
                        <td align="left" rowspan="1" colspan="1">8 (2.2)</td>
                        <td align="left" rowspan="1" colspan="1">6 (1.6)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Coronary artery disease</td>
                        <td align="left" rowspan="1" colspan="1">501 (8.5)</td>
                        <td align="left" rowspan="1" colspan="1">122 (7.0)</td>
                        <td align="left" rowspan="1" colspan="1">131 (7.4)</td>
                        <td align="left" rowspan="1" colspan="1">82 (9.8)</td>
                        <td align="left" rowspan="1" colspan="1">89 (11.2)</td>
                        <td align="left" rowspan="1" colspan="1">44 (12.1)</td>
                        <td align="left" rowspan="1" colspan="1">33 (8.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peripheral artery disease</td>
                        <td align="left" rowspan="1" colspan="1">12 (0.2)</td>
                        <td align="left" rowspan="1" colspan="1">4 (0.2)</td>
                        <td align="left" rowspan="1" colspan="1">3 (0.2)</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.2)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.1)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current smoking</td>
                        <td align="left" rowspan="1" colspan="1">1835 (31.1)</td>
                        <td align="left" rowspan="1" colspan="1">581 (33.1)</td>
                        <td align="left" rowspan="1" colspan="1">572 (32.5)</td>
                        <td align="left" rowspan="1" colspan="1">241 (28.8)</td>
                        <td align="left" rowspan="1" colspan="1">234 (29.4)</td>
                        <td align="left" rowspan="1" colspan="1">101 (27.7)</td>
                        <td align="left" rowspan="1" colspan="1">106 (27.9)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="8" rowspan="1">Type of <italic toggle="yes">CYP2C19</italic> loss‐of‐function allele carrier, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Intermediate metabolizers</td>
                        <td align="left" rowspan="1" colspan="1">4588 (77.8)</td>
                        <td align="left" rowspan="1" colspan="1">1376 (78.5)</td>
                        <td align="left" rowspan="1" colspan="1">1384 (78.6)</td>
                        <td align="left" rowspan="1" colspan="1">631 (75.4)</td>
                        <td align="left" rowspan="1" colspan="1">631 (79.2)</td>
                        <td align="left" rowspan="1" colspan="1">288 (78.9)</td>
                        <td align="left" rowspan="1" colspan="1">278 (73.2)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Poor metabolizers</td>
                        <td align="left" rowspan="1" colspan="1">1305 (22.1)</td>
                        <td align="left" rowspan="1" colspan="1">378 (21.6)</td>
                        <td align="left" rowspan="1" colspan="1">376 (21.4)</td>
                        <td align="left" rowspan="1" colspan="1">206 (24.6)</td>
                        <td align="left" rowspan="1" colspan="1">166 (20.8)</td>
                        <td align="left" rowspan="1" colspan="1">77 (21.1)</td>
                        <td align="left" rowspan="1" colspan="1">102 (26.8)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="8" rowspan="1">Time to randomization after symptom onset, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;12 h</td>
                        <td align="left" rowspan="1" colspan="1">2400 (40.7)</td>
                        <td align="left" rowspan="1" colspan="1">719 (41.0)</td>
                        <td align="left" rowspan="1" colspan="1">703 (40.0)</td>
                        <td align="left" rowspan="1" colspan="1">342 (40.9)</td>
                        <td align="left" rowspan="1" colspan="1">325 (40.8)</td>
                        <td align="left" rowspan="1" colspan="1">164 (44.9)</td>
                        <td align="left" rowspan="1" colspan="1">147 (38.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">≥12 h</td>
                        <td align="left" rowspan="1" colspan="1">3493 (59.3)</td>
                        <td align="left" rowspan="1" colspan="1">1035 (59.0)</td>
                        <td align="left" rowspan="1" colspan="1">1057 (60.1)</td>
                        <td align="left" rowspan="1" colspan="1">495 (59.1)</td>
                        <td align="left" rowspan="1" colspan="1">472 (59.2)</td>
                        <td align="left" rowspan="1" colspan="1">201 (55.1)</td>
                        <td align="left" rowspan="1" colspan="1">233 (61.3)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="8" rowspan="1">Qualifying event, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ischemic stroke</td>
                        <td align="left" rowspan="1" colspan="1">4729 (80.2)</td>
                        <td align="left" rowspan="1" colspan="1">1401 (79.9)</td>
                        <td align="left" rowspan="1" colspan="1">1395 (79.3)</td>
                        <td align="left" rowspan="1" colspan="1">672 (80.3)</td>
                        <td align="left" rowspan="1" colspan="1">651 (81.7)</td>
                        <td align="left" rowspan="1" colspan="1">295 (80.8)</td>
                        <td align="left" rowspan="1" colspan="1">315 (82.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">TIA</td>
                        <td align="left" rowspan="1" colspan="1">1164 (19.8)</td>
                        <td align="left" rowspan="1" colspan="1">353 (20.1)</td>
                        <td align="left" rowspan="1" colspan="1">365 (20.7)</td>
                        <td align="left" rowspan="1" colspan="1">165 (19.7)</td>
                        <td align="left" rowspan="1" colspan="1">146 (18.3)</td>
                        <td align="left" rowspan="1" colspan="1">70 (19.2)</td>
                        <td align="left" rowspan="1" colspan="1">65 (17.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">NIHSS score in patients with ischemic stroke, median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">2 (1–3)</td>
                        <td align="left" rowspan="1" colspan="1">2 (1–3)</td>
                        <td align="left" rowspan="1" colspan="1">2 (1–3)</td>
                        <td align="left" rowspan="1" colspan="1">2 (1–3)</td>
                        <td align="left" rowspan="1" colspan="1">2 (1–3)</td>
                        <td align="left" rowspan="1" colspan="1">2 (1–3)</td>
                        <td align="left" rowspan="1" colspan="1">2 (1–3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median ABCD<sup>2</sup> score in patients with TIA, median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">4 (4–5)</td>
                        <td align="left" rowspan="1" colspan="1">4 (4–5)</td>
                        <td align="left" rowspan="1" colspan="1">4 (4–5)</td>
                        <td align="left" rowspan="1" colspan="1">5 (4–5)</td>
                        <td align="left" rowspan="1" colspan="1">5 (4–5)</td>
                        <td align="left" rowspan="1" colspan="1">5 (4–5)</td>
                        <td align="left" rowspan="1" colspan="1">4 (4–5)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="8" rowspan="1">Previous medication, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Antiplatelet</td>
                        <td align="left" rowspan="1" colspan="1">695 (11.8)</td>
                        <td align="left" rowspan="1" colspan="1">179 (10.2)</td>
                        <td align="left" rowspan="1" colspan="1">180 (10.4)</td>
                        <td align="left" rowspan="1" colspan="1">137 (16.4)</td>
                        <td align="left" rowspan="1" colspan="1">103 (12.9)</td>
                        <td align="left" rowspan="1" colspan="1">44 (12.1)</td>
                        <td align="left" rowspan="1" colspan="1">52 (13.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lipid‐lowering</td>
                        <td align="left" rowspan="1" colspan="1">459 (7.8)</td>
                        <td align="left" rowspan="1" colspan="1">112 (6.4)</td>
                        <td align="left" rowspan="1" colspan="1">119 (6.8)</td>
                        <td align="left" rowspan="1" colspan="1">93 (11.1)</td>
                        <td align="left" rowspan="1" colspan="1">77 (9.7)</td>
                        <td align="left" rowspan="1" colspan="1">32 (8.8)</td>
                        <td align="left" rowspan="1" colspan="1">26 (6.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Extracranial atherosclerotic stenosis, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">520 (8.8)</td>
                        <td align="left" rowspan="1" colspan="1">104 (5.9)</td>
                        <td align="left" rowspan="1" colspan="1">104 (5.9)</td>
                        <td align="left" rowspan="1" colspan="1">121 (14.5)</td>
                        <td align="left" rowspan="1" colspan="1">99 (12.4)</td>
                        <td align="left" rowspan="1" colspan="1">48 (13.2)</td>
                        <td align="left" rowspan="1" colspan="1">45 (11.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Symptomatic extracranial atherosclerotic stenosis, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">268 (4.6)</td>
                        <td align="left" rowspan="1" colspan="1">42 (2.4)</td>
                        <td align="left" rowspan="1" colspan="1">49 (2.8)</td>
                        <td align="left" rowspan="1" colspan="1">74 (8.8)</td>
                        <td align="left" rowspan="1" colspan="1">58 (7.3)</td>
                        <td align="left" rowspan="1" colspan="1">25 (6.9)</td>
                        <td align="left" rowspan="1" colspan="1">20 (5.3)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38919-ntgp-0002">
                    <fn id="jah38919-note-0006">
                      <p>Data are median (IQR) or n (%). ABCD<sup>2</sup> indicates age, blood pressure, clinical finding, duration and diabetes; asICAS, asymptomatic intracranial artery stenosis; ICAS, intracranial artery stenosis; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; sICAS, symptomatic intracranial artery stenosis; and TIA, transient ischemic attack.</p>
                    </fn>
                    <fn id="jah38919-note-0007">
                      <label>*</label>
                      <p>Ethnicity was identified by site investigator and recorded from the front page of the medical record, and this information was sourced from the identification card of participants.</p>
                    </fn>
                    <fn id="jah38919-note-0008">
                      <label>
                        <sup>†</sup>
                      </label>
                      <p>Included Zhuang, Hui, Man, Uighur, and other ethnicities.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Statistical analyses were performed with SAS software version 9.4 (SAS Institute). All tests were 2‐sided, and <italic toggle="yes">P</italic>&lt;0.05 was considered indicative of statistical significance.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah38919-sec-0015">
              <title>RESULTS</title>
              <sec id="jah38919-sec-0016">
                <title>Baseline Characteristics</title>
                <p>Of the 6412 patients who are carriers of <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles enrolled from September 23, 2019 to March 22, 2021 in the CHANCE‐2 trial, 5893 patients were recruited for the current study after excluding 492 patients without available imaging of the intracranial arteries and 27 patients who only completed transcranial Doppler. Of these patients, 5208 (88.4%) underwent MR angiography, 678 (11.5%) underwent CT angiography, and 7 (0.1%) underwent digital subtraction angiography. There were 2956 patients allocated to the ticagrelor–aspirin group and 2937 patients allocated to the clopidogrel–aspirin group. All patients completed 90 days of follow‐up (Figure <xref rid="jah38919-fig-0001" ref-type="fig">1</xref>). No significant differences between included and excluded patients were found (Table <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S1</xref>). There were 2379 patients with ICAS and 3514 patients without ICAS; the characteristics of patients with or without ICAS and different treatment groups are shown in Table <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S2</xref>.</p>
                <fig position="float" fig-type="Figure" id="jah38919-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <title>Study flow diagram for ticagrelor vs clopidogrel treatment in patients in different ICAS groups.</title>
                    <p>asICAS indicates asymptomatic intracranial artery stenosis; ICAS, intracranial artery stenosis; ITT, intention to treat; sICAS, symptomatic intracranial artery stenosis; and TCD, transcranial Doppler.</p>
                  </caption>
                  <graphic xlink:href="JAH3-12-e031611-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
                <p>Among the 5893 patients included, the median age was 64.8 years (IQR, 57.0–71.4), and 1996 (33.9%) patients were women. In regard to the ICAS groups, 3514 patients (59.6%) had no ICAS, 1634 patients (27.7%) had sICAS, and 745 patients (12.7%) had asICAS. Most patients (80.2%) presented with ischemic stroke, and 19.8% presented with TIA. Compared with patients without ICAS, those with sICAS and asICAS had higher median systolic blood pressure values, more risk factors (hypertension, diabetes, previous ischemic stroke, myocardial infarction, and coronary artery disease), and a higher incidence of coexisting extracranial atherosclerotic stenosis (Table <xref rid="jah38919-tbl-0001" ref-type="table">1</xref>).</p>
              </sec>
              <sec id="jah38919-sec-0017">
                <title>Efficacy Outcomes</title>
                <p>When analyzed by different ICAS groups, 172 (4.9%) of the 3514 patients in the without ICAS group, 171 (10.5%) of the 1634 patients in the sICAS group, and 57 (7.7%) of the 745 patients in the asICAS group experienced a new stroke within 90 days. Compared with the cumulative recurrence risk of new stroke in the without ICAS group, the HRs of stroke recurrence in the sICAS and asICAS groups were 2.17 (95% CI, 1.74–2.70) and 1.59 (95% CI, 1.17–2.17) after controlling the randomization group factor, respectively (Figure <xref rid="jah38919-fig-0002" ref-type="fig">2A</xref>). In the patients without ICAS, new stroke within 90 days occurred in 62 (3.5%) of 1754 patients in the ticagrelor–aspirin group and in 110 (6.3%) of 1760 patients in the clopidogrel–aspirin group (HR, 0.57 [95% CI, 0.41–0.78]). In the patients with sICAS, new stroke within 90 days occurred in 81 (9.7%) of 837 patients in the ticagrelor–aspirin group and in 90 (11.3%) of 797 patients in the clopidogrel–aspirin group (HR, 0.77 [95% CI, 0.56–1.05]). However, in the asICAS group, new stroke occurred in 27 (7.4%) of 365 patients in the ticagrelor–aspirin group and 30 (7.9%) of 380 patients in the clopidogrel–aspirin group (HR, 0.77 [95% CI, 0.43–1.38]; Table <xref rid="jah38919-tbl-0002" ref-type="table">2</xref>; Figure <xref rid="jah38919-fig-0002" ref-type="fig">2B</xref> through <xref rid="jah38919-fig-0002" ref-type="fig">2D</xref>). Among the 3 groups, no treatment‐by‐ICAS group interaction was observed (<italic toggle="yes">P</italic> for interaction=0.14; Table <xref rid="jah38919-tbl-0002" ref-type="table">2</xref>). After combining patients with sICAS and asICAS into a single group of patients with ICAS, the cumulative risk of new stroke was consistent with that found in the sICAS or asICAS groups separately (HR, 0.86 [95% CI, 0.66–1.12]; <italic toggle="yes">P</italic> for interaction=0.04; Table <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S3</xref>; Figure <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S1</xref>).</p>
                <fig position="float" fig-type="Figure" id="jah38919-fig-0002">
                  <label>Figure 2</label>
                  <caption>
                    <title>Kaplan‐Meier plots of new stroke in patients with different ICAS groups and treatments.</title>
                    <p><bold>A</bold>, New stroke in all populations with different ICAS status. <bold>B</bold>, New stroke in the ticagrelor–aspirin and clopidogrel–aspirin groups without ICAS. <bold>C</bold>, New stroke in the ticagrelor–aspirin and clopidogrel–aspirin groups with sICAS. <bold>D</bold>, New stroke in the ticagrelor–aspirin and clopidogrel–aspirin groups with asICAS. asICAS indicates asymptomatic intracranial artery stenosis; HR, hazard ratio; ICAS, intracranial artery stenosis; and sICAS, symptomatic intracranial artery stenosis.</p>
                  </caption>
                  <graphic xlink:href="JAH3-12-e031611-g002" position="anchor" id="jats-graphic-3"/>
                </fig>
                <table-wrap position="float" id="jah38919-tbl-0002" content-type="Table">
                  <label>Table 2</label>
                  <caption>
                    <p>Efficacy Outcomes of Ticagrelor–Aspirin and Clopidogrel–Aspirin Treatment in Patients in Different ICAS Groups</p>
                  </caption>
                  <table frame="hsides" rules="all">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1">Outcomes</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Treatment, n (%)</th>
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1">Hazard ratio or odds ratio (95% CI)</th>
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1"><italic toggle="yes">P</italic> value</th>
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1"><italic toggle="yes">P</italic> value for interaction</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Ticagrelor–aspirin<xref rid="jah38919-note-0010" ref-type="table-fn">*</xref> (n=2956)</th>
                        <th align="left" rowspan="1" colspan="1">Clopidogrel–aspirin<xref rid="jah38919-note-0011" ref-type="table-fn">†</xref> (n=2937)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="6" rowspan="1">Primary outcome</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">New stroke</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.14</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1">62 (3.5)</td>
                        <td align="left" rowspan="1" colspan="1">110 (6.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.57 (0.41–0.78)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1">81 (9.7)</td>
                        <td align="left" rowspan="1" colspan="1">90 (11.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.77 (0.56–1.05)</td>
                        <td align="left" rowspan="1" colspan="1">0.10</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1">27 (7.4)</td>
                        <td align="left" rowspan="1" colspan="1">30 (7.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.77 (0.43–1.38)</td>
                        <td align="left" rowspan="1" colspan="1">0.38</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="6" rowspan="1">Secondary outcome</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ischemic stroke</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.14</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1">61 (3.5)</td>
                        <td align="left" rowspan="1" colspan="1">108 (6.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.57 (0.41–0.78)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1">81 (9.7)</td>
                        <td align="left" rowspan="1" colspan="1">89 (11.2)</td>
                        <td align="left" rowspan="1" colspan="1">0.78 (0.56–1.07)</td>
                        <td align="left" rowspan="1" colspan="1">0.12</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1">26 (7.1)</td>
                        <td align="left" rowspan="1" colspan="1">29 (7.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.77 (0.42–1.39)</td>
                        <td align="left" rowspan="1" colspan="1">0.38</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke within 30 d</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.31</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1">55 (3.1)</td>
                        <td align="left" rowspan="1" colspan="1">96 (5.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.57 (0.41–0.80)</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1">63 (7.5)</td>
                        <td align="left" rowspan="1" colspan="1">70 (8.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.76 (0.53–1.09)</td>
                        <td align="left" rowspan="1" colspan="1">0.13</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1">20 (5.5)</td>
                        <td align="left" rowspan="1" colspan="1">27 (7.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.59 (0.31–1.15)</td>
                        <td align="left" rowspan="1" colspan="1">0.12</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Composite vascular events<xref rid="jah38919-note-0012" ref-type="table-fn">‡</xref>
</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.35</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1">83 (4.7)</td>
                        <td align="left" rowspan="1" colspan="1">129 (7.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.64 (0.49–0.85)</td>
                        <td align="left" rowspan="1" colspan="1">0.002</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1">94 (11.2)</td>
                        <td align="left" rowspan="1" colspan="1">104 (13.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.79 (0.59–1.05)</td>
                        <td align="left" rowspan="1" colspan="1">0.09</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1">30 (8.2)</td>
                        <td align="left" rowspan="1" colspan="1">42 (11.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.63 (0.37–1.08)</td>
                        <td align="left" rowspan="1" colspan="1">0.09</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Disabling stroke<xref rid="jah38919-note-0013" ref-type="table-fn">§</xref>
</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.10</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1">22 (1.3)</td>
                        <td align="left" rowspan="1" colspan="1">33 (1.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.59 (0.34–1.02)</td>
                        <td align="left" rowspan="1" colspan="1">0.06</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1">50 (6.0)</td>
                        <td align="left" rowspan="1" colspan="1">41 (5.1)</td>
                        <td align="left" rowspan="1" colspan="1">1.11 (0.72–1.70)</td>
                        <td align="left" rowspan="1" colspan="1">0.65</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1">15 (4.1)</td>
                        <td align="left" rowspan="1" colspan="1">11 (2.9)</td>
                        <td align="left" rowspan="1" colspan="1">1.51 (0.65–3.50)</td>
                        <td align="left" rowspan="1" colspan="1">0.34</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Ordinal stroke or TIA<xref rid="jah38919-note-0014" ref-type="table-fn">ǁ</xref>
</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.32</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.63 (0.47–0.84)</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">No stroke or TIA</td>
                        <td align="left" rowspan="1" colspan="1">1672 (95.3)</td>
                        <td align="left" rowspan="1" colspan="1">1633 (92.8)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">TIA</td>
                        <td align="left" rowspan="1" colspan="1">20 (1.1)</td>
                        <td align="left" rowspan="1" colspan="1">17 (1.0)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mild stroke, mRS 0–1</td>
                        <td align="left" rowspan="1" colspan="1">40 (2.3)</td>
                        <td align="left" rowspan="1" colspan="1">77 (4.4)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Moderate stroke, mRS 2–3</td>
                        <td align="left" rowspan="1" colspan="1">17 (1.0)</td>
                        <td align="left" rowspan="1" colspan="1">25 (1.4)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Severe stroke, mRS 4–5</td>
                        <td align="left" rowspan="1" colspan="1">5 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1">4 (0.2)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fatal stroke, mRS 6</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">4 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.85 (0.64–1.16)</td>
                        <td align="left" rowspan="1" colspan="1">0.31</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">No stroke or TIA</td>
                        <td align="left" rowspan="1" colspan="1">745 (89.0)</td>
                        <td align="left" rowspan="1" colspan="1">695 (87.2)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">TIA</td>
                        <td align="left" rowspan="1" colspan="1">11 (1.3)</td>
                        <td align="left" rowspan="1" colspan="1">12 (1.5)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mild stroke, mRS 0–1</td>
                        <td align="left" rowspan="1" colspan="1">31 (3.7)</td>
                        <td align="left" rowspan="1" colspan="1">49 (6.2)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Moderate stroke, mRS 2–3</td>
                        <td align="left" rowspan="1" colspan="1">31 (3.7)</td>
                        <td align="left" rowspan="1" colspan="1">26 (3.3)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Severe stroke, mRS 4–5</td>
                        <td align="left" rowspan="1" colspan="1">18 (2.2)</td>
                        <td align="left" rowspan="1" colspan="1">13 (1.6)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fatal stroke, mRS 6</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.1)</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.82 (0.50–1.37)</td>
                        <td align="left" rowspan="1" colspan="1">0.45</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">No stroke or TIA</td>
                        <td align="left" rowspan="1" colspan="1">336 (92.1)</td>
                        <td align="left" rowspan="1" colspan="1">343 (90.3)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">TIA</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.6)</td>
                        <td align="left" rowspan="1" colspan="1">7 (1.8)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mild stroke, mRS 0–1</td>
                        <td align="left" rowspan="1" colspan="1">12 (3.3)</td>
                        <td align="left" rowspan="1" colspan="1">19 (5.0)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Moderate stroke, mRS 2–3</td>
                        <td align="left" rowspan="1" colspan="1">9 (2.5)</td>
                        <td align="left" rowspan="1" colspan="1">9 (2.4)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Severe stroke, mRS 4–5</td>
                        <td align="left" rowspan="1" colspan="1">4 (1.1)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Fatal stroke, mRS 6</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.6)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38919-ntgp-0003">
                    <fn id="jah38919-note-0009">
                      <p>Data are n (%) unless otherwise indicated. asICAS indicates asymptomatic intracranial artery stenosis; ICAS, intracranial artery stenosis; mRS, modified Rankin Scale; sICAS, symptomatic intracranial artery stenosis; and TIA, transient ischemic attack.</p>
                    </fn>
                    <fn id="jah38919-note-0010">
                      <label>*</label>
                      <p>Without ICAS n=1754, with sICAS n=837, with asICAS n=365.</p>
                    </fn>
                    <fn id="jah38919-note-0011">
                      <label>
                        <sup>†</sup>
                      </label>
                      <p>Without ICAS n=1760, with sICAS n=797, with asICAS n=380.</p>
                    </fn>
                    <fn id="jah38919-note-0012">
                      <label>
                        <sup>‡</sup>
                      </label>
                      <p>Composite vascular events included ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction, and vascular death.</p>
                    </fn>
                    <fn id="jah38919-note-0013">
                      <label>
                        <sup>§</sup>
                      </label>
                      <p>A stroke was defined as disabling if the patient had a subsequent score on the modified Rankin Scale of &gt;1 (indicating death or any degree of disability).</p>
                    </fn>
                    <fn id="jah38919-note-0014">
                      <label>
                        <sup>ǁ</sup>
                      </label>
                      <p>Severity measured using a 6‐level ordered categorical scale that incorporates subsequent stroke or TIA events and mRS score at 3 months. The common odds ratio is shown rather than the hazard ratio.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>In regard to secondary efficacy outcomes, compared with the cumulative recurrence risk of new stroke in the without ICAS group, the HRs of stroke recurrence in the sICAS and asICAS groups were 2.14 (95% CI, 1.72–2.66) and 1.57 (95% CI, 1.15–2.14), respectively (Figure <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S2A</xref>). Among the patients without ICAS, ischemic stroke within 90 days occurred in 61 (3.5%) of 1754 patients in the ticagrelor–aspirin group versus 108 (6.1%) of 1760 patients in the clopidogrel–aspirin group (HR, 0.57 [95% CI, 0.41–0.78]). Among the patients with sICAS, ischemic stroke occurred in 81 (9.7%) of 837 patients in the ticagrelor–aspirin group versus 89 (11.2%) of 797 patients in the clopidogrel–aspirin group (HR, 0.78 [95% CI, 0.56–1.07]). Among the patients with asICAS, ischemic stroke occurred in 26 (7.1%) of 365 patients in the ticagrelor–aspirin group versus 29 (7.6%) of 380 patients in the clopidogrel–aspirin group (HR, 0.77 [95% CI, 0.42–1.39]). No significant treatment‐by‐ICAS group interaction was observed (<italic toggle="yes">P</italic> for interaction=0.14; Table <xref rid="jah38919-tbl-0002" ref-type="table">2</xref>; Figure <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S2</xref>). The secondary outcomes of stroke within 30 days and composite vascular events both showed trends similar to those found in the primary outcome (Table <xref rid="jah38919-tbl-0002" ref-type="table">2</xref>). After combining both sICAS and asICAS as a single group of patients with ICAS, the cumulative risk of new ischemic stroke was consistent with that found in the sICAS or asICAS groups separately (HR, 0.87 [95% CI, 0.66–1.14]; <italic toggle="yes">P</italic> for interaction=0.04; Table <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S3</xref>).</p>
                <p>In the patients with anterior circulation, new stroke within 90 days occurred in 90 (6.6%) of 1357 patients in the ticagrelor–aspirin group and 136 (10.3%) of 1326 patients in the clopidogrel–aspirin group (HR, 0.64 [95% CI, 0.49–0.84]). In the patients with posterior circulation, new stroke occurred in 44 (6.3%) of 697 patients in the ticagrelor–aspirin group and 61 (8.9%) of 688 patients in the clopidogrel‐aspirin group (HR, 0.60 [95% CI, 0.40–0.89]). The secondary outcomes of ischemic stroke, stroke within 30 days, and composite vascular events both showed trends similar to those found in the primary outcome. No significant treatment‐by‐circulation interaction was observed (all <italic toggle="yes">P</italic> for interaction&gt;0.05; Table <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S4</xref>).</p>
              </sec>
              <sec id="jah38919-sec-0018">
                <title>Safety Outcomes</title>
                <p>In regard to safety outcomes, no significant difference in moderate or severe bleeding was found among the patients in different ICAS groups (5 patients [0.3%] in the ticagrelor–aspirin group versus 5 patients [0.3%] in the clopidogrel‐aspirin group among those without ICAS, with 2 [0.2%] versus 1 [0.1%] event occurring in patients with sICAS, and 2 [0.6%] versus 3 [0.8%] events occurring in patients with asICAS). In the without ICAS group, compared with those receiving clopidogrel–aspirin, patients receiving ticagrelor–aspirin had a nearly triple risk for any bleeding (108 [6.2%] versus 40 [2.3%]) and mild bleeding (103 [5.9%] versus 35 [2.0%]). No significant difference was observed for other safety outcomes. Moreover, no significant treatment‐by‐ICAS group interaction was observed (all <italic toggle="yes">P</italic> for interaction&gt;0.05; Table <xref rid="jah38919-tbl-0003" ref-type="table">3</xref>).</p>
                <table-wrap position="float" id="jah38919-tbl-0003" content-type="Table">
                  <label>Table 3</label>
                  <caption>
                    <p>Safety Outcomes of Ticagrelor–Aspirin and Clopidogrel–Aspirin Treatment in Patients in Different ICAS Groups</p>
                  </caption>
                  <table frame="hsides" rules="all">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1">Outcomes</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Treatment, n (%)</th>
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1"/>
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1"/>
                        <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1"/>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Ticagrelor–aspirin<xref rid="jah38919-note-0016" ref-type="table-fn">*</xref> (n=2956)</th>
                        <th align="left" rowspan="1" colspan="1">Clopidogrel–aspirin<xref rid="jah38919-note-0017" ref-type="table-fn">†</xref> (n=2937)</th>
                        <th align="left" rowspan="1" colspan="1">Hazard ratio or odds ratio (95 CI%)</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value for interaction</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="6" rowspan="1">Bleeding assessment</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Severe or moderate bleeding<xref rid="jah38919-note-0018" ref-type="table-fn">‡</xref>
</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.86</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1">5 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1">5 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1">1.05 (0.30–3.663)</td>
                        <td align="left" rowspan="1" colspan="1">0.95</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.2)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.1)</td>
                        <td align="left" rowspan="1" colspan="1">1.86 (0.17–20.57)</td>
                        <td align="left" rowspan="1" colspan="1">0.61</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.6)</td>
                        <td align="left" rowspan="1" colspan="1">3 (0.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.83 (0.14–5.01)</td>
                        <td align="left" rowspan="1" colspan="1">0.84</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fatal bleeding</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">1.00</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.1)</td>
                        <td align="left" rowspan="1" colspan="1">NA</td>
                        <td align="left" rowspan="1" colspan="1">1.00</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.1)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">NA</td>
                        <td align="left" rowspan="1" colspan="1">1.00</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.6)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1">2.57 (0.23–28.54)</td>
                        <td align="left" rowspan="1" colspan="1">0.44</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Intracranial hemorrhage</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.93</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.1)</td>
                        <td align="left" rowspan="1" colspan="1">3 (0.2)</td>
                        <td align="left" rowspan="1" colspan="1">0.61 (0.10–3.66)</td>
                        <td align="left" rowspan="1" colspan="1">0.59</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.1)</td>
                        <td align="left" rowspan="1" colspan="1">NA</td>
                        <td align="left" rowspan="1" colspan="1">1.00</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1">1.00 (0.06–15.99)</td>
                        <td align="left" rowspan="1" colspan="1">1.00</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Any bleeding</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.11</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1">108 (6.2)</td>
                        <td align="left" rowspan="1" colspan="1">40 (2.3)</td>
                        <td align="left" rowspan="1" colspan="1">2.78 (1.91–4.04)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1">32 (3.8)</td>
                        <td align="left" rowspan="1" colspan="1">20 (2.5)</td>
                        <td align="left" rowspan="1" colspan="1">1.49 (0.82–2.69)</td>
                        <td align="left" rowspan="1" colspan="1">0.19</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1">21 (5.8)</td>
                        <td align="left" rowspan="1" colspan="1">15 (4.0)</td>
                        <td align="left" rowspan="1" colspan="1">1.89 (0.91–3.95)</td>
                        <td align="left" rowspan="1" colspan="1">0.09</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mild bleeding</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.10</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1">103 (5.9)</td>
                        <td align="left" rowspan="1" colspan="1">35 (2.0)</td>
                        <td align="left" rowspan="1" colspan="1">3.04 (2.04–4.51)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1">30 (3.6)</td>
                        <td align="left" rowspan="1" colspan="1">19 (2.4)</td>
                        <td align="left" rowspan="1" colspan="1">1.47 (0.80–2.71)</td>
                        <td align="left" rowspan="1" colspan="1">0.22</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1">19 (5.2)</td>
                        <td align="left" rowspan="1" colspan="1">12 (3.2)</td>
                        <td align="left" rowspan="1" colspan="1">2.29 (1.00–5.20)</td>
                        <td align="left" rowspan="1" colspan="1">0.05</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Death</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">0.44</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Without ICAS</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.1)</td>
                        <td align="left" rowspan="1" colspan="1">6 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.24 (0.05–1.18)</td>
                        <td align="left" rowspan="1" colspan="1">0.08</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With sICAS</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.2)</td>
                        <td align="left" rowspan="1" colspan="1">4 (0.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.47 (0.08–2.63)</td>
                        <td align="left" rowspan="1" colspan="1">0.39</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">With asICAS</td>
                        <td align="left" rowspan="1" colspan="1">4 (1.1)</td>
                        <td align="left" rowspan="1" colspan="1">6 (1.6)</td>
                        <td align="left" rowspan="1" colspan="1">1.37 (0.29–6.40)</td>
                        <td align="left" rowspan="1" colspan="1">0.69</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38919-ntgp-0004">
                    <fn id="jah38919-note-0015">
                      <p>Data are n (%) unless otherwise indicated. asICAS indicates asymptomatic intracranial artery stenosis; ICAS, intracranial artery stenosis; NA, not applicable; and sICAS, symptomatic intracranial artery stenosis.</p>
                    </fn>
                    <fn id="jah38919-note-0016">
                      <label>*</label>
                      <p>Without ICAS n=1754, with sICAS n=837, with asICAS n=365.</p>
                    </fn>
                    <fn id="jah38919-note-0017">
                      <label>
                        <sup>†</sup>
                      </label>
                      <p>Without ICAS n=1760, with sICAS n=797, with asICAS n=380.</p>
                    </fn>
                    <fn id="jah38919-note-0018">
                      <label>
                        <sup>‡</sup>
                      </label>
                      <p>Severe or moderate bleeding and mild bleeding were defined according to the GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) criteria.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>There was no significant difference in safety outcomes including severe or moderate bleeding, fatal bleeding, or intracranial hemorrhage found between different circulations. However, in the anterior circulation group, compared with those receiving clopidogrel–aspirin, patients receiving ticagrelor–aspirin had a higher risk for any bleeding (76 [5.6%] versus 35 [2.6%]) and mild bleeding (72 [5.3%] versus 28 [2.1%]). Similar results were also observed in the posterior circulation. No significant treatment‐by‐circulation interaction was observed (all <italic toggle="yes">P</italic> for interaction&gt;0.05; Table <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S4</xref>).</p>
              </sec>
              <sec id="jah38919-sec-0019">
                <title>Sensitivity Analysis</title>
                <p>In the sensitivity analysis after adjusting for other potential confounders, the adjusted HRs (95% CI) for stroke recurrence were 0.57 (95% CI, 0.41–0.78) in patients without ICAS, 0.75 (95% CI, 0.54–1.01) in patients with sICAS, and 0.78 (95% CI, 0.42–1.46) in patients with asICAS (<italic toggle="yes">P</italic> for interaction=0.18), and the HRs (95% CI) of the secondary efficacy and safety outcomes in different ICAS groups were similar to those without adjustment for confounders (Tables <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S5</xref> and <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S6</xref>). After matching in a ratio of 1:1, there were 720 paired patients with sICAS, 3494 paired patients without ICAS, and 1586 paired patients without ICAS included in this study. The HRs (95% CI) for stroke recurrence were 0.58 (95% CI, 0.42–0.79) in patients without ICAS, 0.74 (95% CI, 0.54–1.03) in patients with sICAS, and 0.73 (95% CI, 0.40–1.32) in patients with asICAS (<italic toggle="yes">P</italic> for interaction=0.24). The differences in secondary efficacy and safety outcomes in different ICAS groups were similar to those before matching (Tables <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S7</xref> and <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S8</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jah38919-sec-0020">
              <title>DISCUSSION</title>
              <p>In the post hoc subgroup analysis performed in the CHANCE‐2 trial, which included patients with acute minor ischemic stroke or TIA who carry <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles, we found that both patients with sICAS and those with asICAS had much higher risk of new stroke than those without ICAS. The efficacy and safety of ticagrelor–aspirin versus clopidogrel–aspirin in preventing new stroke had no significant differences in patients with and without ICAS, whereas the without ICAS group may have received greater benefit from ticagrelor–aspirin therapy.</p>
              <p>As a P2Y12 receptor blocker, ticagrelor was found to be superior to clopidogrel in patients without ICAS who carry <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles. However, ticagrelor therapy reduced the stroke recurrence rate to a lesser extent in patients with sICAS. This superiority was nonsignificant, which may have resulted from the limited sample size of this group. This beneficial trend of ticagrelor–aspirin versus clopidogrel–aspirin in patients with sICAS was consistent with the findings from the PRINCE (Ticagrelor with Aspirin on Platelet Reactivity in acute Non‐disabling Cerebrovascular Events) trial, which was considered a pilot study of the CHANCE‐2 trial.<xref rid="jah38919-bib-0019" ref-type="bibr"><sup>19</sup></xref> However, compared with the benefit of ticagrelor in patients without ICAS, the less beneficial effect of ticagrelor in patients with sICAS might be due to the high burden of recurrent stroke in these patients; ticagrelor plus aspirin may be insufficient in reducing risk, because the 90‐day recurrence rate remained as high as approximately 10.0%, even after dual antiplatelet therapy. The ongoing CAPTIVA (Comparison of Anti‐Coagulation and Anti‐Platelet Therapies for Intracranial Vascular Atherostenosis) trial, comparing the efficacy of ticagrelor, clopidogrel, and rivaroxaban in combination with aspirin in the treatment of ICAS, and conducting a follow‐up of up to 12 months, will provide new ideas for the treatment of intracranial arterial stenosis (<ext-link xlink:href="https://www.clinicaltrials.gov" ext-link-type="uri">https://www.clinicaltrials.gov</ext-link>; Unique identifier: NCT05047172). In our previous analysis of dual antiplatelet therapy in patients with ICAS and high‐sensitivity C‐reactive protein (hs‐CRP) in the CHANCE trial, we found that clopidogrel plus aspirin therapy was effective only in patients with ICAS with nonelevated hs‐CRP (&lt;3 mg/L), not in patients with ICAS with elevated hs‐CRP (≥3 mg/L), who had an approximate 16.0% recurrence rate of 90‐day stroke or combined vascular events.<xref rid="jah38919-bib-0020" ref-type="bibr"><sup>20</sup></xref> Inflammatory hs‐CRP is associated with recurrent vascular events,<xref rid="jah38919-bib-0021" ref-type="bibr"><sup>21</sup></xref> especially among patients with sICAS,<xref rid="jah38919-bib-0022" ref-type="bibr"><sup>22</sup></xref> in whom hs‐CRP reflects the intracranial atherosclerotic burden.<xref rid="jah38919-bib-0023" ref-type="bibr"><sup>23</sup></xref> This could indicate that the inflammatory burden plays an interactive role in the effectiveness of antiplatelet therapy. Therefore, we speculate that the high inflammatory burden might explain why the benefits of ticagrelor–aspirin were not significantly different from those of clopidogrel–aspirin in patients with sICAS in the current study. This hypothesis needs to be verified in future studies, in which a comprehensive strategy of anti‐inflammation plus dual antiplatelet treatment might be warranted.</p>
              <p>In addition, we found that the risk of new stroke in the asICAS group was much higher than that in the without ICAS group, although index stroke was not caused by coexisting artery stenosis. This differs from that reported in the Oxford Vascular Study, in which asymptomatic patients with ICAS did not have an increased risk of recurrent stroke compared with those patients without ICAS.<xref rid="jah38919-bib-0017" ref-type="bibr"><sup>17</sup></xref> The Oxford Vascular Study is well known for its population‐based study design, whereas the current analysis was based on the randomized controlled trial CHANCE‐2, which might have contributed to the disparity in stroke recurrence between both studies.</p>
              <p>In this study, the proportion of patients with sICAS or asICAS was approximately 40%, which was slightly lower than that reported in our previous prospective registry of intracranial artery stenosis among patients with acute ischemic cerebrovascular diseases (46.6%).<xref rid="jah38919-bib-0002" ref-type="bibr"><sup>2</sup></xref> This was probably due to the exclusion of patients who received dual antiplatelet treatment within 72 hours of randomization who might have symptomatic or asymptomatic ICAS.</p>
              <p>After combining both groups of sICAS and asICAS as a whole (with the ICAS group) in the exploratory analysis (Table <xref rid="jah38919-supitem-0001" ref-type="supplementary-material">S3</xref>), we found that the without ICAS group received greater benefit from ticagrelor plus aspirin treatment in preventing the risk of a new stroke, ischemic stroke, and disabling stroke; therefore, we hypothesize that maybe the genetic testing of <italic toggle="yes">CYP2C19</italic> is necessary for patients without ICAS but not for those with ICAS. This trend was similar to that found among the 3 groups (without ICAS group, with sICAS group, with asICAS group), and the underlying mechanism might be considered the same.</p>
              <p>In the present study, moderate or severe bleeding did not differ among the patients in different ICAS groups, but the mild bleeding and any bleeding risk of ticagrelor were higher than clopidogrel in patients without ICAS, which was consistent with the overall results of the CHANCE‐2 trial.<xref rid="jah38919-bib-0012" ref-type="bibr"><sup>12</sup></xref>
</p>
              <sec id="jah38919-sec-0021">
                <title>Strengths and Limitations</title>
                <p>To the best of our knowledge, this is the first study to compare 2 P2Y12 receptor blockers in patients with or without ICAS who carry <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles. Over 90% of eligible patients underwent intracranial vascular imaging, which was predominantly MR angiography. Moreover, the high‐performance quality of the CHANCE‐2 trial with no patients lost to follow‐up ensured the integrity of our findings. However, several limitations also exist. First, our findings may not be generalizable to non‐Asian patients and patients with major stroke, because the CHANCE‐2 trial mainly involved Chinese patients with acute minor ischemic stroke or high‐risk TIA treated within 24 hours after symptom onset. Second, the present study was not a prespecified subgroup analysis, and such treatment‐based heterogeneity effects may be unreliable; further study is needed to confirm it.<xref rid="jah38919-bib-0024" ref-type="bibr"><sup>24</sup></xref> Third, although almost 9% of patients in our study underwent MR angiography, our preferred imaging technique, CT angiography had to be used when MR angiography was contraindicated or unavailable, and the 2 techniques might have different sensitivities and specificities for detecting intracranial artery stenosis. Although CT angiography seems to be more clinically specific, MR angiography is commonly used to detect intracranial artery stenosis due to the risk of contrast agent allergies when CT angiography is used for screening. Finally, the present study sample size is limited. Based on the stroke recurrence rate in carriers of <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles with sICAS in the ticagrelor–aspirin group (9.6%) and clopidogrel–aspirin group (11.4%), the optimal sample size in this group would be 9100 with a power of 0.8, assuming a 2‐sided significance level of 0.05.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="jah38919-sec-0022">
              <title>CONCLUSIONS</title>
              <p>In this post hoc subgroup analysis of the CHANCE‐2 randomized clinical trial, both patients with sICAS and those with asICAS had a much higher risk of new stroke than those without ICAS among carriers of <italic toggle="yes">CYP2C19</italic> loss‐of‐function alleles. Patients without ICAS received a significantly greater benefit from ticagrelor–aspirin after minor ischemic stroke or TIA; however, there was no statistically significant difference between treatments in patients with sICAS or asICAS. The safety of ticagrelor–aspirin versus clopidogrel–aspirin was similar between patients with ICAS and those without ICAS, which was consistent with the overall results of the CHANCE‐2 intention‐to‐treat population.</p>
            </sec>
            <sec id="jah38919-sec-0024">
              <title>Sources of Funding</title>
              <p>This work was supported by grants from the National Natural Science Foundation of China (82171 270, 92046016), Beijing Natural Science Foundation (Z200016), Beijing Municipal Committee of Science and Technology (Z201100005620010), and Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2019‐2M‐5‐029). The funders of the study were not responsible for the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit for publication.</p>
            </sec>
            <sec id="jah38919-sec-0025">
              <title>Disclosures</title>
              <p>None.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="jah38919-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>Data S1</p>
                  <p>Tables S1–S8</p>
                  <p>Figures S1–S2</p>
                </caption>
                <media xlink:href="JAH3-12-e031611-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jah38919-sec-0023">
              <title>Acknowledgments</title>
              <p>The authors thank all study participants, their relatives, and the members of the survey teams at the 202 centers of the CHANCE‐2 study. Both corresponding authors had full access to all of the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. Z.L., C.W., and J.J. were responsible for study design, data acquisition, analysis plan, imaging analysis, data interpretation, and drafting of the article. W.J. was responsible for drafting the article. A.W. and Q.X. were responsible for the analysis. X. Zhang was responsible for imaging analysis. Yongjun Wang was responsible for the study conception, design, supervision, and analysis and interpretation of the data. All other authors were responsible for acquiring data and revising the article.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah38919-bibl-0001">
              <title>References</title>
              <ref id="jah38919-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0001"><string-name><surname>Wong</surname><given-names>LK</given-names></string-name>. <article-title>Global burden of intracranial atherosclerosis</article-title>. <source>Int J Stroke</source>. <year>2006</year>;<volume>1</volume>:<fpage>158</fpage>–<lpage>159</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1747-4949.2006.00045.x</pub-id>
<pub-id pub-id-type="pmid">18706036</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0002"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Soo</surname><given-names>YO</given-names></string-name>, <string-name><surname>Pu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Pan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zou</surname><given-names>X</given-names></string-name>, <string-name><surname>Leung</surname><given-names>TW</given-names></string-name>, <string-name><surname>Cai</surname><given-names>Y</given-names></string-name>, et al. <article-title>Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) study</article-title>. <source>Stroke</source>. <year>2014</year>;<volume>45</volume>:<fpage>663</fpage>–<lpage>669</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.113.003508</pub-id>
<pub-id pub-id-type="pmid">24481975</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0003"><string-name><surname>Hurford</surname><given-names>R</given-names></string-name>, <string-name><surname>Wolters</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Li</surname><given-names>L</given-names></string-name>, <string-name><surname>Lau</surname><given-names>KK</given-names></string-name>, <string-name><surname>Kuker</surname><given-names>W</given-names></string-name>, <string-name><surname>Rothwell</surname><given-names>PM</given-names></string-name>; <collab collab-type="authors">Oxford Vascular Study Phenotyped C</collab>
. <article-title>Prevalence, predictors, and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke: a population‐based cohort study</article-title>. <source>Lancet Neurol</source>. <year>2020</year>;<volume>19</volume>:<fpage>413</fpage>–<lpage>421</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(20)30079-X</pub-id>
<pub-id pub-id-type="pmid">32333899</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0004"><string-name><surname>Chimowitz</surname><given-names>MI</given-names></string-name>, <string-name><surname>Lynn</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Derdeyn</surname><given-names>CP</given-names></string-name>, <string-name><surname>Turan</surname><given-names>TN</given-names></string-name>, <string-name><surname>Fiorella</surname><given-names>D</given-names></string-name>, <string-name><surname>Lane</surname><given-names>BF</given-names></string-name>, <string-name><surname>Janis</surname><given-names>LS</given-names></string-name>, <string-name><surname>Lutsep</surname><given-names>HL</given-names></string-name>, <string-name><surname>Barnwell</surname><given-names>SL</given-names></string-name>, <string-name><surname>Waters</surname><given-names>MF</given-names></string-name>, et al. <article-title>Stenting versus aggressive medical therapy for intracranial arterial stenosis</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>:<fpage>993</fpage>–<lpage>1003</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1105335</pub-id>
<pub-id pub-id-type="pmid">21899409</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0005"><string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Wong</surname><given-names>KS</given-names></string-name>, <string-name><surname>Leng</surname><given-names>X</given-names></string-name>, <string-name><surname>Pu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Jing</surname><given-names>J</given-names></string-name>, <string-name><surname>Zou</surname><given-names>X</given-names></string-name>, <string-name><surname>Pan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>A</given-names></string-name>, <string-name><surname>Meng</surname><given-names>X</given-names></string-name>, et al. <article-title>Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of chance</article-title>. <source>Neurology</source>. <year>2015</year>;<volume>85</volume>:<fpage>1154</fpage>–<lpage>1162</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000001972</pub-id>
<pub-id pub-id-type="pmid">26330567</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0006"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name><surname>Lin</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>H</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>SC</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Pan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name>, et al. <article-title>Association between CYP2C19 loss‐of‐function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>316</volume>:<fpage>70</fpage>–<lpage>78</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2016.8662</pub-id>
<pub-id pub-id-type="pmid">27348249</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0007"><string-name><surname>Pan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yi</surname><given-names>X</given-names></string-name>, <string-name><surname>Han</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Li</surname><given-names>X</given-names></string-name>, <string-name><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>SC</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X</given-names></string-name>, et al. <article-title>Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta‐analysis</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>135</volume>:<fpage>21</fpage>–<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.024913</pub-id>
<pub-id pub-id-type="pmid">27806998</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0008"><string-name><surname>Simon</surname><given-names>T</given-names></string-name>, <string-name><surname>Danchin</surname><given-names>N</given-names></string-name>. <article-title>Clinical impact of pharmacogenomics of clopidogrel in stroke</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>135</volume>:<fpage>34</fpage>–<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.025198</pub-id>
<pub-id pub-id-type="pmid">28028061</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0009"><string-name><surname>Amarenco</surname><given-names>P</given-names></string-name>, <string-name><surname>Albers</surname><given-names>GW</given-names></string-name>, <string-name><surname>Denison</surname><given-names>H</given-names></string-name>, <string-name><surname>Easton</surname><given-names>JD</given-names></string-name>, <string-name><surname>Evans</surname><given-names>SR</given-names></string-name>, <string-name><surname>Held</surname><given-names>P</given-names></string-name>, <string-name><surname>Hill</surname><given-names>MD</given-names></string-name>, <string-name><surname>Jonasson</surname><given-names>J</given-names></string-name>, <string-name><surname>Kasner</surname><given-names>SE</given-names></string-name>, <string-name><surname>Ladenvall</surname><given-names>P</given-names></string-name>, et al. <article-title>Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of socrates, a randomised, double‐blind, controlled trial</article-title>. <source>Lancet Neurol</source>. <year>2017</year>;<volume>16</volume>:<fpage>301</fpage>–<lpage>310</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(17)30038-8</pub-id>
<pub-id pub-id-type="pmid">28238711</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0010"><string-name><surname>Amarenco</surname><given-names>P</given-names></string-name>, <string-name><surname>Denison</surname><given-names>H</given-names></string-name>, <string-name><surname>Evans</surname><given-names>SR</given-names></string-name>, <string-name><surname>Himmelmann</surname><given-names>A</given-names></string-name>, <string-name><surname>James</surname><given-names>S</given-names></string-name>, <string-name><surname>Knutsson</surname><given-names>M</given-names></string-name>, <string-name><surname>Ladenvall</surname><given-names>P</given-names></string-name>, <string-name><surname>Molina</surname><given-names>CA</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>SC</given-names></string-name>, et al. <article-title>Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin</article-title>. <source>Stroke</source>. <year>2020</year>;<volume>51</volume>:<fpage>3504</fpage>–<lpage>3513</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.120.032239</pub-id>
<pub-id pub-id-type="pmid">33198608</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0011"><string-name><surname>Galli</surname><given-names>M</given-names></string-name>, <string-name><surname>Benenati</surname><given-names>S</given-names></string-name>, <string-name><surname>Capodanno</surname><given-names>D</given-names></string-name>, <string-name><surname>Franchi</surname><given-names>F</given-names></string-name>, <string-name><surname>Rollini</surname><given-names>F</given-names></string-name>, <string-name><surname>D'Amario</surname><given-names>D</given-names></string-name>, <string-name><surname>Porto</surname><given-names>I</given-names></string-name>, <string-name><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>. <article-title>Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta‐analysis</article-title>. <source>Lancet</source>. <year>2021</year>;<volume>397</volume>:<fpage>1470</fpage>–<lpage>1483</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00533-X</pub-id>
<pub-id pub-id-type="pmid">33865495</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0012"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Meng</surname><given-names>X</given-names></string-name>, <string-name><surname>Wang</surname><given-names>A</given-names></string-name>, <string-name><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name><surname>Pan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>SC</given-names></string-name>, <string-name><surname>Li</surname><given-names>H</given-names></string-name>, <string-name><surname>Bath</surname><given-names>PM</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Q</given-names></string-name>, <string-name><surname>Xu</surname><given-names>A</given-names></string-name>, et al. <article-title>Ticagrelor versus clopidogrel in CYP2C19 loss‐of‐function carriers with stroke or TIA</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>385</volume>:<fpage>2520</fpage>–<lpage>2530</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2111749</pub-id>
<pub-id pub-id-type="pmid">34708996</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0013"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>C</given-names></string-name>, <string-name><surname>Bath</surname><given-names>PM</given-names></string-name>, <string-name><surname>Meng</surname><given-names>X</given-names></string-name>, <string-name><surname>Jing</surname><given-names>J</given-names></string-name>, <string-name><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name><surname>Wang</surname><given-names>A</given-names></string-name>, <string-name><surname>Pan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname><given-names>A</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Q</given-names></string-name>, et al. <article-title>Clopidogrel with aspirin in High‐risk patients with Acute Non‐disabling Cerebrovascular Events II (CHANCE‐2): rationale and design of a multicentre randomised trial</article-title>. <source>Stroke Vasc Neurol</source>. <year>2021</year>;<volume>6</volume>:<fpage>280</fpage>–<lpage>285</lpage>. doi: <pub-id pub-id-type="doi">10.1136/svn-2020-000791</pub-id>
<pub-id pub-id-type="pmid">33952670</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0014"><string-name><surname>Schulz</surname><given-names>KF</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name><surname>Moher</surname><given-names>D</given-names></string-name>; <collab collab-type="authors">Group C</collab>
. <article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</article-title>. <source>BMJ</source>. <year>2010</year>;<volume>340</volume>:<elocation-id>c332</elocation-id>. doi: <pub-id pub-id-type="doi">10.1136/bmj.c332</pub-id>
<pub-id pub-id-type="pmid">20332509</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0015"><string-name><surname>Moher</surname><given-names>D</given-names></string-name>, <string-name><surname>Hopewell</surname><given-names>S</given-names></string-name>, <string-name><surname>Schulz</surname><given-names>KF</given-names></string-name>, <string-name><surname>Montori</surname><given-names>V</given-names></string-name>, <string-name><surname>Gotzsche</surname><given-names>PC</given-names></string-name>, <string-name><surname>Devereaux</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Elbourne</surname><given-names>D</given-names></string-name>, <string-name><surname>Egger</surname><given-names>M</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>. <article-title>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</article-title>. <source>BMJ</source>. <year>2010</year>;<volume>340</volume>:<elocation-id>c869</elocation-id>. doi: <pub-id pub-id-type="doi">10.1136/bmj.c869</pub-id><pub-id pub-id-type="pmid">20332511</pub-id></mixed-citation>
              </ref>
              <ref id="jah38919-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0016"><string-name><surname>Samuels</surname><given-names>OB</given-names></string-name>, <string-name><surname>Joseph</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Lynn</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Smith</surname><given-names>HA</given-names></string-name>, <string-name><surname>Chimowitz</surname><given-names>MI</given-names></string-name>. <article-title>A standardized method for measuring intracranial arterial stenosis</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2000</year>;<volume>21</volume>:<fpage>643</fpage>–<lpage>646</lpage>.<pub-id pub-id-type="pmid">10782772</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0017"><string-name><surname>Hurford</surname><given-names>R</given-names></string-name>, <string-name><surname>Wolters</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Li</surname><given-names>L</given-names></string-name>, <string-name><surname>Lau</surname><given-names>KK</given-names></string-name>, <string-name><surname>Küker</surname><given-names>W</given-names></string-name>, <string-name><surname>Rothwell</surname><given-names>PM</given-names></string-name>. <article-title>Prognosis of asymptomatic intracranial stenosis in patients with transient ischemic attack and minor stroke</article-title>. <source>JAMA Neurol</source>. <year>2020</year>;<volume>77</volume>:<fpage>947</fpage>–<lpage>954</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2020.1326</pub-id>
<pub-id pub-id-type="pmid">32453401</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0018"><collab collab-type="authors">Investigators G</collab>
. <article-title>An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>1993</year>;<volume>329</volume>:<fpage>673</fpage>–<lpage>682</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJM199309023291001</pub-id>
<pub-id pub-id-type="pmid">8204123</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0019"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Meng</surname><given-names>X</given-names></string-name>, <string-name><surname>Chen</surname><given-names>G</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Cao</surname><given-names>Y</given-names></string-name>, et al. <article-title>Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial</article-title>. <source>BMJ</source>. <year>2019</year>;<volume>365</volume>:<elocation-id>l2211</elocation-id>. doi: <pub-id pub-id-type="doi">10.1136/bmj.l2211</pub-id>
<pub-id pub-id-type="pmid">31171523</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0020"><string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Wang</surname><given-names>A</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Meng</surname><given-names>X</given-names></string-name>, <string-name><surname>Lin</surname><given-names>J</given-names></string-name>, <string-name><surname>Jing</surname><given-names>J</given-names></string-name>, <string-name><surname>Zou</surname><given-names>X</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, et al. <article-title>High‐sensitive C‐reactive protein and dual antiplatelet in intracranial arterial stenosis</article-title>. <source>Neurology</source>. <year>2018</year>;<volume>90</volume>:<fpage>e447</fpage>–<lpage>e454</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000004928</pub-id>
<pub-id pub-id-type="pmid">29330312</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0021"><string-name><surname>Park</surname><given-names>DW</given-names></string-name>, <string-name><surname>Yun</surname><given-names>SC</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JY</given-names></string-name>, <string-name><surname>Kim</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Kang</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SW</given-names></string-name>, <string-name><surname>Kim</surname><given-names>YH</given-names></string-name>, <string-name><surname>Lee</surname><given-names>CW</given-names></string-name>, <string-name><surname>Kim</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Park</surname><given-names>SW</given-names></string-name>, et al. <article-title>C‐reactive protein and the risk of stent thrombosis and cardiovascular events after drug‐eluting stent implantation</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>:<fpage>1987</fpage>–<lpage>1995</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.876763</pub-id>
<pub-id pub-id-type="pmid">19884467</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0022"><string-name><surname>Tuttolomondo</surname><given-names>A</given-names></string-name>, <string-name><surname>Pinto</surname><given-names>A</given-names></string-name>. <article-title>C‐reactive protein and efficacy of antiplatelet therapy in (intracranial) atherosclerosis</article-title>. <source>Neurology</source>. <year>2018</year>;<volume>90</volume>:<fpage>253</fpage>–<lpage>254</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000004937</pub-id>
<pub-id pub-id-type="pmid">29330313</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0023"><string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name><surname>Li</surname><given-names>N</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Gao</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>A</given-names></string-name>, <string-name><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X</given-names></string-name>. <article-title>Associations of high sensitivity C‐reactive protein levels with the prevalence of asymptomatic intracranial arterial stenosis</article-title>. <source>Eur J Neurol</source>. <year>2014</year>;<volume>21</volume>:<fpage>512</fpage>–<lpage>518</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ene.12342</pub-id>
<pub-id pub-id-type="pmid">24447587</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38919-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah38919-cit-0024"><string-name><surname>Rothwell</surname><given-names>PM</given-names></string-name>. <article-title>Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>365</volume>:<fpage>176</fpage>–<lpage>186</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(05)17709-5</pub-id>
<pub-id pub-id-type="pmid">15639301</pub-id>
</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
